Estrogen and Progesterone Receptors of Adenomyosis in Postmenopausal Breast Cancer Patients Treated with Tamoxifen

Ilan Cohen, Cohen I, I Cohen, Jeremiah Shapira, J Shapira, Shapira J, Beyth Y, Y Beyth, Jöelle Bernheim, Bernheim J, J Bernheim, Tepper R, R. Tepper, M Cordoba, Cordoba M, Mario Cordoba, Altaras MM, M M Altaras, Marco M. Altaras
Gynecologic and obstetric investigation · 1998 · vol. 45(2) , pp. 126–131 · doi:10.1159/000009939 · PMID:9517806 · W2058784171
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

Estrogen and progesterone receptor levels in adenomyotic and endometrial tissues of postmenopausal breast cancer patients on tamoxifen were analyzed and found to be similar to controls, with lower ER in adenomyosis than endometrium.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Adenomyosis is an ectopic endometrial tissue located in the myometrium. It has been reported to develop at a higher rate among postmenopausal breast cancer patients on tamoxifen (TAM) treatment than in untreated patients. It has also been reported to be stimulated by estrogen. Assessing receptor levels in adenomyotic tissue may indicate the adenomyotic cell's potential to interact with TAM. In the present study the estrogen receptor (ER) and progesterone receptor (PR) were analyzed by an immunohistochemical technique in adenomyotic and the corresponding endometrial tissues of 14 postmenopausal breast cancer patients treated with TAM and in 15 healthy postmenopausal patients who served as controls. All TAM-treated patients had normal postmenopausal serum estradiol levels. Overall the ER and PR contents in adenomyotic tissue (42.9 and 71.4%) and in the endometriotic tissue (64.3 and 78.6%) obtained from the study patients were similar to those obtained from the control group (adenomyosis, ER and PR = 46.7 and 86.7%; endometrium, ER and PR = 40 and 73.3%; p = NS). In the study group, the ER content was lower in the adenomyotic (42.9%) than in the endometriotic tissue (64.3%). No correlation was found between the duration of TAM therapy, the TAM dosage level or the ER or PR content in the adenomyotic or endometrial tissues. The finding of a relatively low ER content in the adenomyotic tissue than in the endometriotic tissue in postmenopausal TAM-treated patients without endogenous estrogens, similar to that observed in healthy premenopausal women, may be attributed to the estrogen-like effect of TAM.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Breast Neoplasms Endometriosis Postmenopause Receptors, Estrogen Receptors, Progesterone Tamoxifen Aged Antineoplastic Agents, Hormonal Breast Neoplasms Endometriosis Endometriosis Endometrium Endometrium Female Humans Middle Aged Myometrium Myometrium Receptors, Estrogen Receptors, Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Cited by (6)

Source provenance

europepmc
last seen: 2026-07-31T06:09:14.520117+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0 · commercial use OK